Enzyme Inhibitor

US FDA approves first enzyme-blocking antiviral in 20 years

25-Oct-2018 By Maggie Lynch

The US FDA approved Xofluza for the treatment of acute uncomplicated influenza, the first antiviral flu treatment to be approved in almost 20 years.

CDMO roundup: DPT rejig, UDG expansion and Dalton contract

10-Jul-2015 By Dan Stanton

An operational rejig at DPT Laboratories, an expansion at UDG, and a synthesis and toxicology testing contract win for Dalton – welcome to Outsourcing-Pharma’s CDMO round-up.

Ambit Biosciences announces collaboration first with Cephalon

08-Nov-2006 By Wai Lang Chu

Ambit Biosciences has entered into a discovery and development
collaboration with pharmaceutical company Cephalon, signifying the
first time a pharma company has decided to characterise their
entire library of potential drugs based...

Scientists target Aurora B in cancer fight

27-Oct-2006 By Wai Lang Chu

The next generation of anti-cancer drugs took a positive step
forward after scientists successfully inhibited an enzyme that is
responsible for catalysing uncontrolled and abnormal cell
divisions.

Reference tool aids drug discovery

08-Oct-2004

Tool supplier, EMD Biosciences has released the first comprehensive
guide to inhibitors for signal transduction and drug discovery
research that will enable researchers to pinpoint specific enzymes
as a possible target for drug therapy.

TransTech and Merck Initiate $26 Million collaboration

10-Sep-2004

TransTech Pharma and Merck has announced a $26 million research
collaboration using TransTech's proprietary TTP Translational
Technology to discover and develop novel small molecules for a
therapeutic target of interest to Merck.

Small is beautiful for biotech bellwethers

12-Jan-2004

Genentech's strategy of expanding beyond its traditional territory
of protein-based drugs and into small molecules has been reinforced
by a new agreement with Array BioPharma.

Mega licensing deals for biotech firms

09-Sep-2003

Two $500m-plus licensing deals reveal the rewards available to
biotech firms with novel drugs, but also the lengths large
biopharma companies will now go to secure exclusive rights to
promising candidates, even if they are in the...

Inflammation investigated

06-Feb-2003

US Pharmacopeia has entered into a research collaboration focused
on inflammation with Celgene Corporation. The companies will work
together to identify promising small molecule lead compounds
suitable for further development.